Susan G. Komen for the Cure®, the world’s leading breast cancer organization, today launched a major new outreach to dramatically improve cancer screening, education and outreach in the Latina community, where breast cancer is the leading cause of cancer death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50756-susan-g-komen-for-the-cure-latina-community-improve-breast-cancer-outreach
On Sunday, September 25, Kohl’s Department Stores presented the 13th Annual Susan G. Komen Southeast Wisconsin Race for the Cure. Kohl’s once again had the largest team for this year’s race and fielded the largest team in the history of the Susan G. Komen Southeast Wisconsin Race for the Cure, with more than 5,000 team members – more than double the size of last year’s team.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51399-kohls-susan-g-komen-southeast-wisconsin-race-for-the-cure-2011
An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP).
PSP is a rare neurodegenerative brain disease, similar to Parkinson’s disease, which causes severe disability by destroying parts of cells that allow the brain to function normally. While PSP has underlying biological similarities to Alzheimer’s disease, a disease which primarily affects memory, PSP impacts a person’s physical movement and bodily functions. PSP leads to progressive decline in patients — there is no known cause or cure.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/psp/49958/
For seventeen year old Emerson Cole, life is about seeing what is not there. She has tried everything, but the visions keep coming back. So when her well meaning brother brings in a consultant from a secretive organization called the Hourglass, Emerson is willing to try one last cure. But meeting Michael Weaver may not only change her future, it may also change her past. Learn more about this book here, http://bit.ly/eWLbYv and its author here, http://bit.ly/fihKf9 YA
On June 5, CVS/pharmacy kicked-off its 10th annual in-store fundraising campaign -- “Researching a Cure” -- to support the fight against amyotrophic lateral sclerosis (ALS). Funds raised through the campaign benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research. Through the Researching a Cure campaign, CVS/pharmacy has raised more than $23 million in its stores and online at www.cvs.com, to fund new clinical research with the aim of discovering a treatment or cure for ALS. The 2011 campaign will run through June 25.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/50475/
Re-fueling at the pump is a constant source of horror for most drivers, with prices of 1.50 euros per liter of Super now the norm. So it only makes sense that our scientists should be searching for a way to cure us of our petroleum addiction. And the solution could come from advanced, high-efficiency electric motors. This is the domain of electric mobility, which has its own dedicated tradeshow at HANNOVER MESSE, the world’s leading industrial technology fair. The latest electric mobility technology promises to save not just money, but the environment as well.
Legacy®, through an unrestricted educational grant from Genentech, launches two new resources devoted to helping smokers understand their risks for lung cancer and reducing their risks for mortality.
Lung cancer is the nation's number one cancer killer of both men and women, accounting for 28 percent of all cancer deaths. More Americans are killed by lung cancer than by breast cancer, prostate cancer, or any other cancer. Up to 90 percent of lung cancer cases result from smoking and no current treatment can cure lung cancer. Early detection is the key to better quality and longevity of life.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/legacy/47244/
http://naturalremedyforhemorrhoids.com/
Natural Remedy For Hemorrhoids, Easy Method Cures Hemorrhoids Safely in 48 Hours, Already PROVEN By Thousands To Have Eliminated Pain & Embarrassment For Good
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
CVS/pharmacy has kicked-off its ninth annual in-store fund raising campaign to support the fight against amyotrophic lateral sclerosis (ALS). Since 2002, CVS/pharmacy has partnered with the ALS Therapy Alliance (ATA) to help advance ALS research. To date, CVS/pharmacy has raised more than $19 million in its stores—a single $1 donation at a time—to support the funding of new clinical research with the aim of discovering a treatment or cure for this devastating disease. This year's campaign began on June 6 and runs through June 26.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/44466/
